September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
Risk of Stroke May Diminish with Age in Persons with Diabetes and Hypertension: New Findings
The magnitude of the association with age did not change, however, for other stroke risk factors, including smoking, atrial fibrillation, and LVH, investigators report.
Body Weight Related to Beneficial Effects of SGLT-2 Inhibitors in Patients with Type 2 Diabetes in New Analysis
The beneficial effects of SGLT-2 inhibitors in reducing CV death and heart failure hospitalization in patients with T2D are related to body weight, suggest new data.
Daily Dose: Exercise and Incident Diabetes in Adults With Obesity
Your daily dose of clinical news you may have missed.
Aerobic Exercise May Reduce Long-term T2D Risk in Persons with Obesity
Risk of T2D was reduced by 49% over a 10-year follow up period among study participants who followed a vigorous or moderate exercise plan vs those who did not engage in exercise.
Study: Bariatric Surgery Linked to Significant Decrease in Mortality at 40-year Follow-up
A pivotal study with 40-year follow-up of post-bariatric surgery patients reinforces long-term benefits of the procedures on all-cause and cause-specific mortality.
Daily Dose: Improved Glycemic Control and NAFLD in Type 2 Diabetes
FDA Approves SGLT2 Inhibitor Bexagliflozin to Treat Type 2 Diabetes in Adults
Bexagliflozin significantly improved glycemic control in adults when used as monotherapy, in combination with metformin, or when added to several SOC regimens.
Improved HbA1c in Adults with T2D Had Beneficial Impact on NAFLD, According to New Study
Adults with T2D may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to findings from a retrospective analysis.
Metformin Treatment in T2D Patients May Reduce Risk for Joint Replacement: Population-based Study
Investigators report a 30% reduced risk of total joint replacement in persons with type 2 diabetes treated with metformin vs those who did not receive the drug.
FDA Approves Label Update for Semaglutide as a First-line Type 2 Diabetes Medication
The update removes a previous limitation that stated semaglutide should not be used as an initial therapy for treating patients with T2D.
Diabetes in US Youth Projected to Surge Dangerously by 2060
Diabetes cases in the US among those younger than age 20 years, if left unchecked, are projected to increase by more than 600% by 2060, according to new projections.
Osteoporosis May Affect More than One-quarter of Persons with Type 2 Diabetes: Global Meta-analysis
A global prevalence of osteoporosis among persons with T2D of more than 25% calls for greater focus on screening for and managing the bone loss disease in this population.
Greater Glycemic Control May Impact Biological Aging in Adults with Type 2 Diabetes
Optimal glycemic control (less than 7%) in participants from the Look AHEAD trial was associated with smaller increases in frailty index score vs poorer control over the 8-year study period.
Type 2 Diabetes: Top Papers in 2022
Find a compact sampling of 2022 research on type 2 diabetes and its treatment reviewed on Patient Care, chosen by the editorial staff.
Chronic Kidney Disease: Top Papers in 2022
Find a compact sampling of 2022 chronic kidney disease research reviewed on Patient Care, chosen by the editorial staff.
Treat Obesity as a Risk Factor, not a Prerequisite for Pediatric T2D Screening
About one-quarter of children with T2D are not obese, according to a meta-analysis, making comprehensive screening essential in the population.
FDA Clears Dexcom G7 CGM System for Persons with T1D and T2D
The Dexcom G7 continuous glucose monitoring system provides an overall MARD of 8.2%, the highest of any FDA-cleared CGM, the company says.
Empagliflozin Reduces HbA1c, FPG in Pediatric Population with Type 2 Diabetes
Empagliflozin is the first SGLT-2 inhibitor to demonstrate a statistically significant reduction in HbA1c in children and adolescents with type 2 diabetes.
Diabetes and Obesity: Why Obesity Treatment Should Come First
An obesity specialist explains why clinicians should start at the root cause when managing patients with type 2 diabetes and obesity.
How to Build an Obesity Phenotype Step-by-Step, with Andres Acosta, MD, PhD
Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.
Obesity Phenotypes Explain What Drives the Disease and How to Target Intervention: Expert Interview
Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.
Andres Acosta, MD, Discusses the Challenge of Heterogeneity in Response to Obesity Treatment
Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.
AACE President Discusses New Guideline Recommendations for Cardiorenal Protective Therapy in T2D
Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.
Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update
AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.
Obesity Research Roundup for Primary Care: 5 Studies At-a-Glance from ObesityWeek® 2022
Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.
Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
AACE President Sethu Reddy, MD, Highlights Updated 2022 Diabetes Guidelines for Primary Care
Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.
Investigational Glucagon Receptor/GLP-1 Receptor Dual Agonist Bests Semaglutide for Weight Loss in T2D Patients
ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.
Daily Dose: Low-carb Diet May Help Improve Untreated HbA1c